The improving sales bode well for the future as well as the the clinical trials imo. Major changes to team last year could be assisting the turnaround as it takes time to make a difference. Improving sales. imminent further approvals , further expansion , clinical trials is the reason imo you are not seeing much dumping into the bid. Major volume into the mid one cent area could assist a parabolic move forward which seems more a question of when rather than if.
The improving sales bode well for the future as well as the the...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.020(2.00%) |
Mkt cap ! $14.50M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 99.5¢ | $44.55K | 44.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 192 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 6234 | 1 |
View Market Depth
| Last trade - 15.48pm 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |